Education
About Us
Working with TipRanks
Follow Us
Skye Bioscience (SKYE)
NASDAQ:SKYE
SKYE Stock Chart & Stats
$1.11
-$0.06(-1.95%)
At close: 4:00 PM EST
$1.11
-$0.06(-1.95%)
Day’s Range― - ―
52-Week Range$1.14 - $5.75
Previous CloseN/A
Volume18.00K
Average Volume (3M)352.87K
Market Cap
$38.79M
Enterprise Value$120.90M
Total Cash (Recent Filing)$35.31M
Total Debt (Recent Filing)$321.85K
Price to Earnings (P/E)―
Beta3.03
Next Earnings
Mar 19, 2026EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding32,057,460
10 Day Avg. Volume240,287
30 Day Avg. Volume352,867
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.52
Price to Sales (P/S)0.00
P/FCF Ratio-3.85
Enterprise Value/Market Cap3.12
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.39
Forecast
1Y Price Target
$9.80Price Target Upside782.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.38
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsSkye’s Phase 2a CBeyond data confirmed nimacimab’s biological activity with a statistically significant nearly 3% incremental benefit in combination with semaglutide, improved body composition, and rebound mitigation, all with a clean safety profile.
Market PotentialGiven the sizable addressable market in the obesity space, even modest penetration could translate to significant upside for investors.
Safety ProfileNimacimab produced incremental, clinically meaningful weight loss without added safety liabilities when combined with semaglutide.
Bears Say
Baseline ImbalancesImbalances in patient baseline characteristics could influence results.
Clinical EfficacyMonotherapy nimacimab did not meet the primary endpoint for weight loss.
Efficacy ConcernsMonotherapy efficacy was limited at the 200 mg dose, indicating suboptimal exposure.
Skye Bioscience News
SKYE FAQ
What was Skye Bioscience’s price range in the past 12 months?
Skye Bioscience lowest stock price was $1.14 and its highest was $5.75 in the past 12 months.
What is Skye Bioscience’s market cap?
Skye Bioscience’s market cap is $38.79M.
When is Skye Bioscience’s upcoming earnings report date?
Skye Bioscience’s upcoming earnings report date is Mar 19, 2026 which is in 105 days.
How were Skye Bioscience’s earnings last quarter?
Skye Bioscience released its earnings results on Nov 10, 2025. The company reported -$0.32 earnings per share for the quarter, missing the consensus estimate of -$0.314 by -$0.006.
Is Skye Bioscience overvalued?
According to Wall Street analysts Skye Bioscience’s price is currently Undervalued.
Does Skye Bioscience pay dividends?
Skye Bioscience does not currently pay dividends.
What is Skye Bioscience’s EPS estimate?
Skye Bioscience’s EPS estimate is -0.3.
How many shares outstanding does Skye Bioscience have?
Skye Bioscience has 32,057,460 shares outstanding.
What happened to Skye Bioscience’s price movement after its last earnings report?
Skye Bioscience reported an EPS of -$0.32 in its last earnings report, missing expectations of -$0.314. Following the earnings report the stock price went up 2.817%.
Which hedge fund is a major shareholder of Skye Bioscience?
Currently, no hedge funds are holding shares in SKYE
Skye Bioscience Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.80 (782.88% Upside)
$9.80 (782.88% Upside)
Blogger Sentiment
Bullish
SKYE Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 60.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-73.05%
12-Months-Change
Fundamentals
Return on Equity
-94.31%
Trailing 12-Months
Asset Growth
-49.32%
Trailing 12-Months
Company Description
Skye Bioscience
Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 that is in preclinical trials to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California.
SKYE Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture with strong financial health and promising Phase 2a study results highlighting the potential of Nimazumab in combination with semaglutide. However, increased R&D expenses, a larger net loss, concerns about monotherapy efficacy, and limited study enrollment were notable challenges.View all SKYE earnings summariesSKYE Stock 12 Month Forecast
Average Price Target
$9.80
▲(782.88% Upside)
Technical Analysis
Actinium Pharmaceuticals
―
Outlook Therapeutics
―
Bioxcel Therapeutics
―
Inmune Bio
―
Lantern Pharma
―
Ownership Overview
Currently, No data available
---